Related Experiment Video
Updated: Jun 26, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Long-Term Outcomes After Multiorgan Resection of Primary Gastrointestinal Stromal Tumors
Julian Musa1,2,3,4, Franziska Willis1,2, Sarah M Kochendoerfer1
1From the Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Background:
Complete resection is the mainstay of therapy for nonmetastatic gastrointestinal stromal tumors (GIST) and may necessitate multiorgan resection (MOR). We evaluated surgical oncological outcomes as well as long-term quality of life (QoL) in patients undergoing MOR or single-organ resection (SOR) for primary GIST.
Methods:
One hundred fifty-two primary GIST resections performed at Heidelberg University Hospital (2002-2022) were retrospectively analyzed, including subgroup analyses for locally advanced GIST (T3/T4, n = 76). Kaplan-Meier and multivariable Cox regression analyses assessed overall survival (OS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). QoL was evaluated using standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, Warwick-Edinburgh Mental Well-Being Scale, Fear of Progression Questionnaire, and Primary Care PTSD Screen).
Results:
One hundred two (67.1%) patients with primary GIST underwent SOR, and 50 (32.9%) underwent MOR. Five-year OS was 87% in the SOR and 95% in the MOR group. Patients in the MOR group exhibited tumors with higher Armed Forces Institute of Pathology risk scores (P = 0.012) and had more complications (P < 0.001), though the severity of complications was similar. Multivariable analyses revealed no statistically significant difference between MOR and SOR regarding OS and DMFS, but MOR was associated with reduced LRFS (P = 0.001). These associations were consistent in subgroup analyses of locally advanced tumors. Long-term QoL after MOR was noninferior to long-term QoL after SOR.
Conclusions:
MOR is comparable to SOR regarding OS, despite patients undergoing MOR having more prognostically unfavorable tumors. While MOR is associated with increased postoperative morbidity, long-term QoL remains unaffected. Thus, MOR appears oncologically effective when necessary in certain clinical scenarios and does not compromise long-term patient-reported QoL.
